Date of Conferral



Doctor of Nursing Practice (DNP)




Joanne Minnick


Abstract Inhaled Insulin, Afrezza, Educational Module for Health Care Providers

bySara Doolin-Thompson

MSN, Walden University, 2014 BSN, University of Phoenix, 2004 ASN, Kentucky Wesleyan College, 1994

Project Submitted in Partial Fulfillmentof the Requirements for the Degree of Doctor of Nursing Practice

Walden University August 2021 Abstract Diabetes is on a global rise and there is a definite gap in providing care for the diabetic population. Two of the largest contributors to this gap in care are the lack of collaboration between health care professionals and the lack of education for health care providers on the evolution of diabetes treatment plans. This educational module is aimed to improve the management of care, and quality of life for patients living with diabetes, by providing education to health care providers on an alternative way to administer insulin therapy. The describing, analyzing, theorizing, and act, (DATA) model, and the theory of organizational change, were utilized in the development of this educational module. The key project question addressed the following: When health care providers are educated on the guidelines and effectiveness of the inhaled insulin, Afrezza, this educational module would improve professional knowledge when managing the care of patients living with diabetes. Quantitative and qualitative information were gathered by review of peer-reviewed articles and published, evidence-based practice guidelines. The pre-and posttest for the educational program outcomes and quality improvement measures were influenced by the Kirkpatrick evaluation model. This educational module was used to promote knowledge in the health care profession by providing education to twenty health care providers and stakeholders on the guidelines for the use, benefits, and effectiveness of using the inhaled insulin, Afrezza. The outcomes of this project resulted in an overall gain of 137.3% of knowledge on the use of inhaled insulin, Afrezza. The Food and Drug Administration has approved Afrezza, and with its use can promote positive social change, by reducing the number of daily injections, improve the quality of life for patients living with Diabetes, and reduce environmental biohazard materials globally.